Eli Lilly, a leading pharmaceutical company, has launched Copellor® (Ixekizumab) in India following approval from The Drug Controller General of India (DCGI). The drug is designed to treat moderate-to-severe plaque psoriasis and active psoriatic arthritis in adult patients who are candidates for systemic therapy or phototherapy. Copellor® is a humanized IgG4 monoclonal antibody that specifically targets IL-17A, a protein responsible for triggering and maintaining inflammation in psoriasis.
The launch of Copellor® reinforces Eli Lilly’s commitment to bringing innovative medicines to India and providing healthcare providers with new treatment options. Vineet Gupta, Managing Director, Eli Lilly and Company – India & India Subcontinent, said that psoriasis has a significant impact on a patient’s quality of life, and the availability of a new treatment like Copellor® will empower healthcare providers with another option for treating patients with moderate-to-severe plaque psoriasis and active psoriatic arthritis, which is a significant unmet need in the country.
Copellor® is a prescription medicine that is recommended for use only under medical supervision and advice from a dermatologist or rheumatologist. It is available in a single-dose prefilled autoinjector with one strength of 80 mg/ml. The launch of Copellor® provides a new treatment option for patients in India suffering from moderate-to-severe plaque psoriasis and active psoriatic arthritis, and it is a testament to Eli Lilly’s ongoing commitment to bringing innovative treatments to patients in India and around the world.